Regulation of Ischemic Neuronal Death by E2F4-p130 Protein Complexes

Grace O. Iyirhiaro, Yi Zhang, Carmen Estey, Michael J. O’Hare, Farzaneh Safapour, Mohammad Parsanejad, Suzi Wang, Elizabeth Abdel-Messih, Steve M. Callaghan, Matthew J. During, Ruth S. Slack, and David S. Park

From the Department of Cellular and Molecular Medicine and Neuroscience, University of Ottawa, Ottawa, Ontario K1H 8M5, Canada and the Department of Molecular Virology, Immunology, and Medical Genetics, Neurological Surgery, College of Medicine, The Ohio State University, Columbus, Ohio 43210

Background: The contribution of E2F4 to hypoxic/ischemic neuronal death is understood poorly.

Results: Loss of E2F4 leads to an increase in B-Myb and contributes to hypoxic/ischemic neuronal death.

Conclusion: E2F4 is important for survival following hypoxic/ischemic neuronal death.

Significance: Targeting E2F4–repressive functions may be important in maintaining neuronal survival under hypoxic/ischemic conditions.

Inappropriate activation of cell cycle proteins, in particular cyclin D/Cdk4, is implicated in neuronal death induced by various pathologic stresses, including DNA damage and ischemia. Key targets of Cdk4 in proliferating cells include members of the E2F transcription factors, which mediate the expression of cell cycle proteins as well as death-inducing genes. However, the presence of multiple E2F family members complicates our understanding of their role in death. We focused on whether E2F4, an E2F member believed to exhibit crucial control over the maintenance of a differentiated state of neurons, may be critical in ischemic neuronal death. We observed that, in contrast to E2F1 and E2F3, which sensitize to death, E2F4 plays a crucial protective role in neuronal death evoked by DNA damage, hypoxia, and global ischemic insult both in vitro and in vivo. E2F4 occupies promoter regions of proapoptotic factors, such as B-Myb, under basal conditions. Following stress exposure, E2F4–p130 complexes are lost rapidly along with the presence of E2F4 at E2F-containing B-Myb promoter sites. In contrast, the presence of E2F1 at B-Myb sites increases with stress. Furthermore, B-Myb and C-Myb expression increases with ischemic insult. Taken together, we propose a model by which E2F4 plays a protective role in neurons from ischemic insult by forming repressive complexes that prevent prodeath factors such as Myb from being expressed.

Inappropriate activation of the cell cycle machinery is implicated in a number of neuronal death models induced by NGF deprivation (1), excitotoxicity (2), oxidative stress (3), DNA damage (4), and stroke (5–8). For example, an increase in cyclin D1 levels and its associated kinase activity is observed following DNA damage (an upstream mediator of stroke damage) and ischemic insult (5, 7, 9–11). In addition, treatment with pharmacologic cyclin-dependent kinase (Cdk) inhibitors such as flavopiridol protects neurons from both DNA damage- and ischemia-induced cell death (4, 6, 7). Expression of a dominant negative form of Cdk4, an important regulator of the G1/S phase of the cell cycle, is protective following DNA damage and global cerebral ischemia (5, 9). Together, these studies reveal a crucial role for Cdk4 in neuronal death induced by DNA damage and ischemic insult. However, the downstream effectors of cell cycle reactivation in neurons under ischemic stress remain unclear. In this regard, members of the E2F transcription factors may play a pivotal role.

The E2Fs consist of eight related family members, generally classified as activators (E2F1, E2F2, and E2F3a) or repressors (E2F3b and E2F4–E2F8) on the basis of their ability to promote or repress gene transcription (12). The activity of E2Fs (E2F1–E2F5) is regulated by their association with the pocket proteins, which include retinoblastoma protein (pRb), p107, and p130 (12, 13). E2F association with pocket proteins can promote or repress the expression of its targets, which include genes involved in cell cycle progression, DNA damage, and apoptosis (12, 13). For example, in dividing cells, pRb association with E2F prevents the expression of genes required for DNA synthesis and cell cycle progression. However, phosphorylation of pRb by Cdk4/6 disrupts its association with E2F and results in the transactivation of its target genes. In addition to transactivation, E2F complexes can also repress gene function. For example, E2F4–p130 can recruit chromatin modification factors, such as histone deacetylases (HDACs), to promoters of target genes to form an active repression complex (13–16). In this scheme, phosphorylation of p130 by Cdks disrupts its associa-

*This work was supported by grants from the Heart and Stroke Foundation of Canada, the Heart and Stroke Foundation of Ontario, the Canadian Institute of Health Research, the Center for Stroke Recovery, and the Neuroscience Canada/Krembil Foundation (to D. S. P.).
1Recipient of a Heart and Stroke Foundation of Canada doctoral award and the Queen Elizabeth II Graduate Scholarships in Science and Technology award.
2Heart and Stroke Foundation of Canada scholar and recipient of the Heart and Stroke Foundation of Canada Career Investigator award. To whom correspondence should be addressed: Dept. of Cellular and Molecular Medicine, Neuroscience, University of Ottawa, 451 Smyth Rd., Ottawa, ON K1H 8M5, Canada. Tel.: 613-562-5800, ext. 8816; Fax: 613-562-5403; E-mail: dpark@uottawa.ca.

3The abbreviations used are: Cdk, cyclin-dependent kinase; AAV, adeno-associated virus; CGN, cerebellar granule neuron; 4VO, four-vessel occlusion; CA1, cornu ammonis 1.
tion with E2F4, resulting in the derepression of target genes. Thus, E2Fs can function as effectors of Cdk signaling via the transactivation or derepression of target genes.

The involvement of E2F and, in particular, E2F1 in the cell cycle-induced death of neurons under pathologic stress is suggested by a number of key observations. First, phosphorylation of pRb, a preferred partner for activating E2Fs such as E2F1, is observed in neuronal death models, including DNA damage and ischemia (6, 7, 17). Second, the expression of mutant pRbR or dominant negative DP-1, a binding partner of E2Fs, prevents neuronal death following DNA damage and/or hypoxia (5, 17). Finally, E2F1 deficiency is protective following ischemic insult both in vitro and in vivo (8, 18, 19). These observations suggest that cell cycle reactivation in neurons under pathologic stress signals death through pRb inactivation and activation or derepression of E2F1 target genes.

In addition to E2F1 and pRb, other E2Fs may also be important in neuronal death. E2F4-p130 complexes are present basally in postmitotic neurons, suggesting that they may act to repress gene targets important in neuronal survival/function (16, 20). Interestingly, in the absence of insult, siRNA-mediated down-regulation of p130 or E2F4 induced apoptosis of cortical neurons (21). In addition, the expression of wild-type or phosphorylation-resistant p130 is protective following ischemic insult both in vitro and in vivo (8). These observations suggest that cell cycle reactivation in neurons under pathologic stress signals death through pRb inactivation and activation or derepression of E2F1 target genes.

In this study we examined the potential involvement of E2F4 in neuronal death models. The expression of E2F4, which is in contrast to the role of activating E2Fs such as E2F1/3, is observed in neuronal death models, including DNA damage and ischemia (6, 7, 17). Alternatively, CGNs were infected with an adenovirus expressing E2F1, E2F4, or GFP at the time of plating and examined for survival at the indicated times, as described previously (30). Cortical cultures from transgenic mice and CGNs were lysed at the designated times after insult using a mildly disruptive lysis buffer and evaluated as described previously (5). Neurons cotransfected with E2F and GFP plasmids were fixed and stained with Hoechst 33342 (Sigma). Viability was assessed by nuclear integrity in GFP-positive cells in random fields, as described previously (29).

**Hypoxia**—CGN cultures were subjected to hypoxia at 1% O2 with 5% CO2-balanced N2 in a humidified hypoxia chamber (Coy Laboratory Products, Ann Arbor, MI) after 1 week in culture, as described previously (5). Hypoxia was induced in the presence of 10 μM camptothecin (Sigma) 3–4 days after plating and examined for survival at the indicated times, as described previously (30).

**Viral Injection**—Animal experiments were carried out in accordance with Canadian Council for the Use and Care of Animals in Research guidelines with approval from the Ottawa Animal Care Committee. Intrahippocampal, recombinant, adeno-associated viral injections in rats have been described previously (5). Briefly, male Wistar rats (80–125 g) were injected unilaterally with the recombinant adeno-associated virus carrying an enhanced green fluorescent protein (EGFP) control or E2F4 (1010 genomes/μl) 2 weeks before a four-vessel occlusion insult. 2 μl of recombinant adeno-associated virus diluted in PBS with 1 μl of mannitol (20%) was injected stereotaxically using a Harvard infusion pump (Harvard Apparatus) into the hippocampus (from the bregma, −3.6 mm anteroposterior, +2.1 mm lateral, and −2.75 mm deep).

**Global Cerebral Ischemia**—The four-vessel occlusion (4VO) method of global ischemia was induced as described previously for 10 min (6, 32). Four days following ischemia, rats were perfused and sacrificed, and the brains were extracted, sectioned, and stained for histological assessment. The neuronal viability of cells in the hippocampal CA1 was assessed as described previously (6, 32).

**Immunohistochemistry**—Antigen retrieval and deparaffinization was carried out on brain sections as described previously (32). Following permeabilization with 0.3% Triton X-100 for 10 min, rat brain sections were blocked in 10% normal goat serum (Jackson ImmunoResearch Laboratories) diluted in 2% bovine serum albumin (Fisher Scientific) in 0.01 M PBS for 1 h at room temperature. Sections were incubated with mouse mono-
clonal anti-GFP (Abcam) or anti-E2F4 antibodies (Abcam, 1:200) overnight at 4 °C. For visualization, sections were incubated with Alexa Fluor 488 goat anti-mouse (1:200) secondary antibody (Jackson ImmunoResearch Laboratories) for 1 h at room temperature. Neuronal nuclei were stained with Hoechst 33342 (Sigma).

**Immunoprecipitation**—CGNs were harvested and homogenized in immunoprecipitation buffer (50 mM HEPES (pH 7.5), 150 mM NaCl, 1 mM EDTA, 2.5 mM EGTA, 1 mM DTT, and 0.1% Tween 20) supplemented with protease inhibitor mixture (Roche). 500 μg of total protein lysate was incubated with 4 μg of anti-E2F4 (Santa Cruz Biotechnology) or anti-p130 antibody (Santa Cruz Biotechnology) overnight at 4 °C. As a control, samples were incubated with normal rabbit IgG (Santa Cruz Biotechnology). The antigen-antibody complex was captured with anti-rabbit Ig immunoprecipitation beads (eBiosciences) at 4 °C for 4 h. The beads were recovered, and the immunoprecipitation product was resolved on a 10% SDS-polyacrylamide gel.

**Western Blotting**—Cell and hippocampal tissue samples were collected at the designated times after insult and homogenized in solubilization buffer (0.0625 x Tris, 2.5 mM EDTA, 2.5 mM EGTA, 10% glycerol, 2% SDS, 0.001% bromphenol blue, and 5% β-mercaptoethanol) (24). Alternatively, E2F4 null CGNs or siRNA-transfected cultures were harvested and homogenized in solubilization buffer. Samples were run on SDS-polyacrylamide gels and transferred onto a PVDF membrane (Millipore). Membranes were probed with the following antibodies: anti-E2F4 (Abcam), anti-p130 (BD Transduction Laboratories), anti-phospho-p130 (Santa Cruz Biotechnology), anti-E2F3 (Santa Cruz Biotechnology), and anti β-actin (Sigma). Densitometry was performed on Western blots using ImageJ software and normalized to the loading control. The results were expressed as the fold change over the ratio of the protein to loading control. The results were expressed as fold change over no hypoxia control.

**Luciferase Assay**—One day after plating, CGNs were infected with wild-type or mutant luciferase viruses along with AAV-β-galactosidase as an internal control. After hypoxia/reoxygenation, cells were lysed in buffer provided in the Promega luciferase system (Promega). The luciferase assay was performed according to the instructions of the manufacturer. Relative luciferase activities were obtained by normalizing the luciferase activity against β-galactosidase activity. Results were presented as fold increase in reference to control values.

**RESULTS**

**E2F Family Members Differentially Regulate Neuronal Death Mediated by Genotoxic Stress**—Aberrant activation of neuronal cell cycle induced by pathologic stress such as DNA damage and ischemic insult is thought to contribute to cell death through regulation of E2F members (7, 17, 33). However, the relative contribution of different E2F members in neuronal death is not clear. To begin to examine the involvement of different E2F members, we focused initially on the effect of select activating E2Fs (E2F1 and E2F3) and the repressive E2F4 members in neuronal death. Primary cortical neurons null for these E2F members were treated with the DNA-damaging agent camptothecin and evaluated for survival. Neurons null for E2F1 (Fig. 1A) and E2F3 (Fig. 1B) were more resistant to DNA damage-induced death when compared with those from their littermate controls. E2F1−/− neurons were significantly more resistant to DNA-induced death at 8 h (59% survival, p < 0.01) and 12 h (23% survival, p < 0.05) compared with the wild-type control (43 and 13% survival at 8 and 12 h, respectively). Similarly, neuronal survival in the E2F3−/− neurons (59 and 27%) was greater than that observed for the wild type (43 and 20%, p < 0.01 and p < 0.05 at 8 and 12 h, respectively). In contrast, E2F4 deficiency resulted in sensitization to DNA damage-induced death at 12 h (21% survival) compared with the wild-type control (44%, p < 0.01, Fig. 1C).

We next tested the effect of expression of E2F1, E2F3, and E2F4 on neuronal death induced by DNA damage. As shown in Fig. 1, D–F, expression of E2F1 (Fig. 1D) and E2F3 (Fig. 1E) significantly (p < 0.01) reduced neuronal survival compared with neurons transfected with vector only. In contrast, overexpression of E2F4 (Fig. 1F) resulted in an increase in neuronal survival (46% in vector- and 65% in E2F4-expressing neurons, p < 0.01). Together, these results demonstrate a proapoptotic
role for E2F1 and E2F3 and a prosurvival role for E2F4 in neuronal death induced by DNA damage.

E2F1 and E2F4 Have Opposing Effects on Neuronal Survival following Hypoxia/Reoxygenation—We next determined the effect of E2Fs in a more physiologically relevant model of ischemic neuronal death in vitro with a focus on E2F1 and E2F4. To this end, primary CGNs infected with an adenovirus expressing E2F1, E2F4, or GFP were subjected to 18 h of hypoxia in the presence of MK801, followed by reoxygenation for 24 h. Neurons treated in this fashion die in a delayed manner dependent upon cell cycle activation (5). Consistent with our observation with DNA damage, the expression of E2F1 (Fig. 2A) significantly reduced neuronal survival compared with the GFP control (24% survival in E2F1 knockout neurons, p < 0.01). In contrast, expression of E2F4 was significantly protective following hypoxia/reoxygenation compared with the GFP control (65% survival in E2F4 knockout neurons, p < 0.01) (Fig. 2A).

Loss of function studies were consistent with the observations above (Fig. 2, C and D). In this regard, we focused on the role of E2F4 because loss of function studies with E2F1 following ischemic insult have been shown previously to promote survival (8, 18, 19, 34). CGNs were transfected with siRNA to E2F4 or control siRNA and subjected to hypoxia and reoxygenation. E2F4 knockdown in transfected cultures was verified by Western blot analysis (Fig. 2B). Evaluation of other E2Fs, including E2F1 and E2F3, showed that the levels of these proteins were not affected significantly by E2F4 siRNA-mediated knockdown.4 We observed sensitization of neurons to death induced by hypoxia/reoxygenation when E2F4 was transiently knocked down (3% survival) compared with the siRNA control (29% survival, p < 0.001). Interestingly, neurons transfected with E2F4 siRNA were remarkably more vulnerable to neuronal death even in the absence of insult (19% survival in E2F4 knockdown versus 84% in siRNA control cultures, p < 0.001) (Fig. 2C). CGNs from E2F4−/− and E2F4+/+ mice were also similarly subjected to hypoxia/reoxygenation. E2F4−/− neurons also showed an increased sensitivity to hypoxia-induced neuronal death (23% survival in E2F4 null versus 58% in wild-type neurons, p < 0.01) (Fig. 2D). These results suggest that, unlike E2F1, E2F4 plays a prosurvival role in neuronal death induced by hypoxia. Interestingly, the increased sensitization of E2F4 siRNA-treated neurons to death in the absence of insult suggests a potential compensatory effect in E2F4 knockout neurons. To examine this possibility, we analyzed E2F1 and E2F3 protein levels in E2F4 wild-type and knockout neurons by Western blot analysis. Our results showed that the E2F1 protein level is unaffected by the loss of E2F4 (Fig. 2E and F). However, the E2F3 protein level was reduced significantly (p < 0.05) with germ line E2F4 loss (Fig. 2G and H). This is in contrast with our earlier observation that E2F3 levels are unaffected by the transient knockdown of E2F4.4

E2F4 and p130 Proteins Are Reduced following Hypoxia/Reoxygenation in Vitro—E2F4 is known to form repressive complexes with p130 in neurons, which may be important in neuronal survival (21). Coimmunoprecipitation experiments showed that E2F4 and p130 normally form complexes in CGN (Fig. 3A). This is in accordance with previous reports (23, 35). We then asked whether there were perturbations in total E2F4 and p130 protein levels following hypoxia/reoxygenation insult. CGN cultures were subjected to varying durations of hypoxia or 18 h of hypoxia, followed by reoxygenation times. Total protein was harvested at the indicated times and analyzed by Western blot analysis (Fig. 3B). The blots were probed with antibody against E2F4 (Fig. 3B) or p130 (Fig. 3D). E2F4 (Fig. 3B and C) protein levels were diminished significantly (p < 0.05) following 18 h of hypoxia (R0) and remained reduced for up to 8 h following reoxygenation when compared with untreated cultures. Although there was a reinduction of E2F4 levels at 2 and 4 h of reoxygenation, it did not reach the levels of untreated controls. Similar to E2F4, p130 (Fig. 3D and E) protein levels were also reduced drastically (p < 0.05) immediately following hypoxia, with a brief reinduc-

---

4 G. O. Iyirihiaro, Y. Zhang, F. Safarpour, S. M. Callaghan, R. S. Slack, and D. S. Park, unpublished data.
FIGURE 2. E2F1 and E2F4 have opposing roles in neuronal death induced by hypoxia. A, primary CGN cultures were infected with adenovirus expressing E2F1, E2F4, or GFP control at the time of plating and treated with hypoxia after a week in culture for 18 h, followed by reoxygenation for 24 h. B, Western blot analysis showing E2F4 knockdown in CGN cultures treated with E2F4 siRNA mixture. Ctrl, control. C, CGNs were transfected with E2F4 or control siRNA 5 days after plating. Cultures were treated with 18 h of hypoxia followed by 24 h of reoxygenation 2 days after transfection. D, CGNs from E2F4 KO and wild-type mice were similarly treated with 18 h of hypoxia and 24 h of reoxygenation. Neuronal survival was evaluated 24 h after hypoxia. Results are expressed as percent of control/H11006 S.E. E, E2F1 protein levels are unaffected by E2F4 deficiency. CGNs from E2F4/H11001/H11001 and E2F4/H11002/H11002 neurons were subjected to Western blot analysis and probed with anti-E2F1 antibody and anti-β-actin as a control. F, quantitation of E2F1 levels as in E. G, E2F3 protein levels are diminished in E2F4 knockout neurons. A Western blot analysis was conducted on E2F4/H11001/H11001 and E2F4/H11002/H11002 CGNs. E2F3 was detected using anti-E2F3 antibody. β-actin was used as a loading control. H, quantitation of E2F3 protein levels as in G by densitometry. The protein levels of E2F1 (E) and E2F3 (G) were normalized to β-actin. Error bars represent the mean ± S.E. (n ≥ 3). *, p < 0.05; **, p < 0.01; ***, p < 0.001.
tion at 2 and 4 h of reoxygenation. The reason for this induction is unclear at the moment. However, levels appeared to diminish again thereafter. The loss of p130 could be related to the loss of E2F4 following hypoxia and reoxygenation. Indeed, a Western blot analysis performed on E2F4/H11002/CGN cultures showed that p130 protein levels were diminished significantly (p < 0.05) in the absence of E2F4 (Fig. 3, F and G).

**FIGURE 3.** p130 and E2F4 protein levels are down-regulated following hypoxia/reoxygenation of CGNs in culture. A, E2F4 forms a complex with p130 in CGNs. Total cell lysates from CGN cultures were subjected to reciprocal immunoprecipitation (IP) with anti-E2F4 and anti-p130 antibodies. Immune complexes were resolved by Western blot (WB) analysis and probed with anti-E2F4 and anti-p130 antibodies. B, Western blot analysis showing a loss of E2F4 protein in CGNs subjected to varying durations of hypoxia or 18 h of hypoxia with varying durations of reoxygenation. NH, no hypoxia; C, densitometry was performed on E2F4 blot as in B. E2F4 protein levels were normalized to the actin control. H, hypoxia; R, reoxygenation; R0, 18 h of hypoxia and 0 h of reoxygenation. D, Western blot analysis showing the loss of p130 following different durations of hypoxia or 18 h of hypoxia with varying reoxygenation times. E, densitometry was performed on p130 protein levels as in D and normalized to the β-actin control. F, basal p130 protein levels were diminished in E2F4−/− CGNs. A Western blot analysis was conducted on total protein lysate obtained from E2F4−/− and E2F4+/− CGN cultures. The blots were probed with anti-p130 antibody and anti-β-actin as a control. G, densitometry was conducted on p130 blots as in F. p130 levels were normalized to β-actin. Error bars represent the mean ± S.E. (n ≥ 3). *, p < 0.05.

Hypoxia/Reoxygenation Induces a Concomitant Reduction of E2F4 and Induction of E2F1 Binding at the B-Myb Promoter—

The previous evidence indicates that p130 is lost following ischemia. We next determined how E2F members such as E2F1 or E2F4 might differ in binding to known E2F sites. In this regard, we focused on B-Myb, a prodeath factor described previously for neurons and regulated by E2Fs (21, 35). We examined the relative promoter occupancy of both E2F1 and E2F4 following hypoxia/reoxygenation in vitro. ChIP was carried out on lysates from CGN cultures treated with 18 h of hypoxia and 16 h of reoxygenation using E2F1- and E2F4-specific antibodies. E2F1- and E2F4-associated chromatin was subjected to PCR using B-Myb promoter-specific primers. As shown in Fig. 4A, endogenous E2F4 occupancy at the B-Myb promoter was present in the untreated, no hypoxia samples under basal conditions. This occupancy decreased with hypoxia/reoxygenation (Fig. 4, A and B). This contrasts with E2F1, where occupancy is low under basal conditions and increases with hypoxic stress (Fig. 4, A and C). Consistent with the loss of E2F4, a ChIP analysis performed using p130-specific antibody also showed that it is lost from the B-Myb promoter following hypoxia/reoxygenation (Fig. 4, D and E). Interestingly, we
found that, in the absence of E2F4, p130 is lost from the B-Myb promoter under basal conditions. This result indicates that E2F1 and E2F4 may mutually regulate B-Myb in an opposing manner to increase B-Myb expression and promote death. The ChIP experiments were performed at later time points where we could observe robust biochemical changes. To query the effects of E2F regulation at earlier time points, we next examined changes in E2F-mediated activity at the B-Myb promoter utilizing more sensitive, luciferase-based promoter assays. To this end, CGNs were infected with AAV expressing E2F reporter constructs, B-Myb-promoter-luciferase containing wild-type or mutated E2F sites as a control, and β-galactosidase. Cells were treated with 18 h of hypoxia followed by reoxygenation for up to 8 h. Luciferase activity and β-galactosidase were measured at the indicated times. Data represent values of luciferase/β-galactosidase activity. G, a luciferase assay was conducted in E2F4 wild-type and knockout CGNs treated with 18 h of hypoxia followed by 4 h of reoxygenation. Error bars represent mean ± S.E. (n = 3). *, p < 0.05; **, p < 0.01; ***, p < 0.005.

FIGURE 4. Reduction of E2F4 and induction of E2F1 binding at the B-Myb promoter following hypoxia and reoxygenation. A, ChIP was conducted with E2F4 and E2F1 antibody on CGNs treated with hypoxia (hyp) for 18 h, followed by reoxygenation (reoxy) for 16 h. B, densitometry of the B-Myb signal following ChIP performed with anti-E2F4 antibody as shown in A. Loss of E2F4 was observed at the B-Myb promoter following hypoxia and reoxygenation. C, quantitation of the B-Myb signal following ChIP with anti-E2F1 antibody. D, ChIP was performed with anti-p130 antibody. p130 binding at the B-Myb promoter was lost following hypoxia and reoxygenation. E, densitometry of the B-Myb signal following ChIP as shown in D. F, E2F activity increased after hypoxia and reoxygenation in CGNs. Cells were infected with AAV expressing B-Myb-promoter-luciferase with wild-type E2F or a mutated E2F site and β-galactosidase. Cells were treated with 18 h of hypoxia followed by reoxygenation for up to 8 h. Luciferase activity and β-galactosidase were measured at the indicated times. Data represent values of luciferase/β-galactosidase activity. G, a luciferase assay was conducted in E2F4 wild-type and knockout CGNs treated with 18 h of hypoxia followed by 4 h of reoxygenation. Error bars represent mean ± S.E. (n = 3). *, p < 0.05; **, p < 0.01; ***, p < 0.005.
E2F4 Expression Is Protective following Transient Cerebral Ischemia in Vivo—To further investigate the role of E2F4 under ischemic conditions, we next examined its effects in an *in vivo* model of stroke induced by global ischemia. AAV expressing E2F4 or GFP control were injected unilaterally into the hippocampal CA1 region 2 weeks prior to insult, as described previously (5). Global ischemia was induced for 10 min using the four-vessel occlusion method, as described previously (6, 32). E2F4 overexpression and efficiency of viral delivery were verified by immunohistochemistry staining of CA1 neurons (Fig. 5A) and confirmed by Western blot analysis performed on hippocampal protein lysate from AAV-injected rats (Fig. 5D).

Analysis of CA1 neurons 4 days following global ischemia showed significantly more live CA1 neurons (55% survival) in E2F4-expressing rats compared with those expressing GFP (3%, *p* < 0.05) (Fig. 5, B and C). GFP or E2F4 overexpression alone had no effect on neuronal viability in the absence of insult (Fig. 5C).

***E2F4 and p130 Proteins Are Diminished following Global Ischemia***—We also asked whether perturbations in E2F4 and p130 levels occurred *in vivo* following cerebral ischemia. Similar to the results obtained in CGNs, coimmunoprecipitation results showed that E2F4 and p130 also normally form complexes in rat hippocampal lysates. To examine potential changes in E2F4 and p130 protein levels *in vivo* following ischemia, rats were subjected to 10 min of 4VO and sacrificed at various times following reperfusion, as described under “Experimental Procedures.” Hippocampal lysates were extracted and subjected to Western blot analysis (Fig. 6A). The blots were probed with antibody against p130, E2F4, and actin for a loading control. p130 levels were increased (although not statistically significant) at early time points following ischemia but declined precipitously 24 h following reperfusion (Fig. 6, A and B). The early increase in p130 could be a compensatory response. Similarly to p130, the E2F4 protein level was reduced dramatically reduced 24 h following ischemia (Fig. 6, A and C). The biological function of p130 (14, 36) as well as its stability and down-regulation (37) are known to be regulated by Cdk-mediated phosphorylation. p130 has been shown to contain multiple Cdk phosphorylation sites, including Ser-952 (36). Therefore, we examined p130 Ser-952 phosphorylation following ischemia *in vivo*. Cdk-mediated phosphorylation of Ser-952 was increased following cerebral ischemia (Fig. 6, D and E). These results indicate that p130 is phosphorylated at early time points following ischemic insult and that both p130 and E2F4 proteins are subsequently lost in the death process. These results are similar to those observed with hypoxia/reoxygenation *in vitro*.

***B- and C-myb Transcripts Are Induced following Global Ischemia in Vivo***—Because our results showed that E2F activity is increased at the B-myb promoter *in vitro*, we examined potential changes in its transcript levels as well as that of the related C-Myb following ischemic insult *in vivo*. We observed that both B-Myb (Fig. 7, A and B) and C-Myb (Fig. 7, C and D)
mRNA transcript levels were increased 3-fold (p < 0.05) 24 h following global ischemia. Overall, our results suggest that E2F4-p130 complexes provide neuronal protection under ischemic stress by regulating the expression of proapoptotic factors. Consistent with this hypothesis and previous reports (23, 35), we found that siRNA-mediated knockdown of the C-Myb gene provided protection for neurons subjected hypoxia/reoxygenation insult (Fig. 7F). CGN cultures were transfected with siRNA to C-Myb or control siRNA 5 days after plating and subjected to 18 h of hypoxia followed by 16 h of reoxygenation. Analysis of neuronal survival showed increased neuronal survival in neurons transfected with C-Myb siRNA (56%) compared with control siRNA (37%) (Fig. 7F). Knockdown of the C-Myb message was verified by semiquantitative RT-PCR in siRNA-treated cultures 24 h after transfection (Fig. 7E).

DISCUSSION
Cell cycle induced death of neurons has been described in numerous cell death paradigms (1, 20, 38–40). However, the downstream effectors of this pathway in the context of pathologic neuronal death are not fully understood, particularly in the context of ischemic damage. In this regard, a growing body of evidence suggests that death following ischemic insult is mediated via pRb-E2F1.

In line with this, we found that E2F1 deficiency was protective, whereas its overexpression exacerbated death induced by DNA damage and hypoxia/reoxygenation. Our data are consistent with a proapoptotic role demonstrated previously for E2F1 in other contexts, including death induced by staurosporine (41), β-amyloid (42), potassium deprivation (24, 43, 44), kainic acid (34), oxygen-glucose deprivation (OGD) (8), and ischemia (8, 24, 34, 41, 42). Similar to E2F1, E2F3, another member of the activating E2F family, is proapoptotic. Overexpression of E2F3 promoted cell death in response to camptothecin treatment, whereas its down-regulation was protective. This is in line with a previous report demonstrating a protective role for E2F3 deficiency in the developing CNS in response to DNA damage (45).

The role of the repressive E2F4 contrasts that of activating E2F members by promoting survival under conditions of ischemic stress. This is supported by several findings in this study. Acute down-regulation of E2F4 in CGNs using siRNA caused death in the absence of insult. Hypoxia/reoxygenation resulted in death that was exacerbated with E2F4 deficiency and knock-
down in culture. In contrast, we found that overexpression of E2F4 protected neurons from death induced by hypoxia/reoxygenation in vitro and global cerebral ischemia in vivo. The data presented here as well as by others (8, 18, 19) demonstrate that, in the context of cerebral ischemic damage, the activities of both the activating and repressive E2Fs are an important determinant of neuronal survival and death.

The differential roles of activating and repressive E2Fs in neuronal survival is interesting. Although the exact reasoning behind this role is not clear, there are some intriguing hypotheses generated by our data. First, we showed that p130-E2F4 levels are present basally but reduced following ischemic insult. Second, we show that E2F4 binding to the E2F site on the B-Myb promoter is reduced following ischemia.

**FIGURE 7.** B- and C-Myb mRNA transcript levels are increased following global cerebral ischemia. A, semiquantitative RT-PCR of the B-Myb message following global ischemia. Rats were subjected to 10 min of 4VO followed by 12 and 24 h of reperfusion. Hippocampal tissues were extracted and analyzed by semiquantitative RT-PCR. GAPDH is shown as a control. B, densitometry of B-Myb levels. Data are expressed as fold over sham-operated control. C, semiquantitative RT-PCR of the C-Myb message following 4VO as described in A. E, semiquantitative RT-PCR showing siRNA mediated knockdown of the C-Myb message 24 h following transfection. S12 is shown as a loading control. F, C-Myb knockdown protects CGNs from hypoxia/reoxygenation insult. Neurons were transfected with C-Myb siRNA and subjected to 18 h of hypoxia followed by 16 h of reoxygenation. Error bars represent the mean ± S.E. (n ≥ 3). *, p < 0.05.
E2F4-p130 Complexes in Hypoxia/Ischemia in Neurons

hypoxia. This suggests a model where p130-E2F4 exists basally to form active repressive complexes but is lost after death-inducing insult. These repressive complexes may be critical for neuronal survival. In support of this, p130 predominantly occupies E2F sites in cultured neurons (21) and has been shown, along with E2F4, to participate in the mammalian DP, Rb-like, E2F and MuvB-like (DREAM) protein complex (46). Additionally, p130 levels are high in neurons (47, 48), and p130 loss has been suggested to promote death (49). In particular, p130 deficiency leads to strain-dependent lethality in null mice (49), and its down-regulation in cultured neurons promotes apoptosis (21).

In this scenario, we suggest that E2F4 is protective because it would facilitate the formation of repressive complexes, which are lost following ischemic insult. In contrast to E2F4, we propose that E2F1 acts to promote death by directly activating prodeath genes. This is supported in this study by the observation that E2F1 is prodeath and that its occupancy on death-inducing genes is increased following hypoxic insult. Therefore, we propose a model whereby hypoxia/ischemia leads to the loss of E2F4-repressive complexes on target promoters and allows for increase in E2F1 transactivating activity on those genes. Both would then contribute to an increase in expression of targets such as Myb, leading to death. Indeed, we show that targets such as B-Myb and C-Myb are increased following ischemia in vivo. It will be important to fully test this hypothesis in the future.

Acknowledgment—We thank Yasmilde Rodriguez Gonzalez for critical reading of the manuscript.

REFERENCES

1. Park, D. S., Levine, B., Ferrari, G., and Greene, L. A. (1997) Cyclin dependent kinase inhibitors and dominant negative cyclin dependent kinase 4 and 6 promote survival of NGF-deprived sympathetic neurons. J. Neurosci. 17, 8975–8983
2. Park, D. S., Obeidat, A., Giovanni, A., and Greene, L. A. (2000) Cell cycle regulators in neuronal death evoked by excitotoxic stress: implications for neurodegeneration and its treatment. Neurobiol. Aging 21, 771–781
3. Schwartz, E. I., Smilenov, L. B., Price, M. A., Osredkar, T., Baker, R. A., Ghosh, S., Shi, F. D., Vollmer, T. L., Lencinas, A., Sterns, D. M., Gorospe, M., and Kruman, I. I. (2007) Cell cycle activation in postmitotic neurons is essential for DNA repair. Cell Cycle 6, 318–329
4. Park, D. S., Morris, E. J., Greene, L. A., and Geller, H. M. (1997) G/S cell cycle blockers and inhibitors of cyclin-dependent kinases suppress campathicin-induced neuronal apoptosis. J. Neurosci. 17, 1256–1270
5. Rashidian, J., Iyihiari, G., Aleyasin, H., Rios, M., Vincent, I., Callaghan, S., Bland, R. J., Slack, R. S., During, M. J., and Park, D. S. (2005) Multiple cyclin-dependent kinases signals are critical mediators of ischemia/hypoxic neuronal death in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 102, 14080–14085
6. Wang, F., Corbett, D., Osuga, H., Osuga, S., Ikeda, J. E., Slack, R. S., Hogan, M. J., Hakim, A. M., and Park, D. S. (2002) Inhibition of cyclin-dependent kinases improves CA1 neuronal survival and behavioral performance after global ischemia in the rat. J. Cereb. Blood Flow Metab. 22, 171–182
7. Osuga, H., Osuga, S., Wang, F., Petri, R., Hogan, M. J., Slack, R. S., Hakim, A. M., Ikeda, J. E., and Park, D. S. (2000) Cyclin-dependent kinases as a therapeutic target for stroke. Proc. Natl. Acad. Sci. U.S.A. 97, 10254–10259
8. Gandrond, T. F., Mealing, G. A., Paris, J., Lou, A., Edwards, A., Hou, S. T., MacManus, J. P., Hakim, A. M., and Morley, P. (2001) Attenuation of neurotoxicity in cortical cultures and hippocampal slices from E2F1 knockout mice. J. Neurochem. 78, 316–324
9. Ferguson, K. L., Callaghan, S. M., O’Hare, M. J., Park, D. S., and Slack, R. S. (2000) The Rb-CDK4/6 signaling pathway is critical in neural precursor cell cycle regulation. J. Biol. Chem. 275, 33593–33600
10. Katchanov, J., Harms, C., Gertz, K., Hauck, L., Waeger, C., Hirt, L., Priller, J., von Harsdorf, R., Bruck, W., Hortegn, H., Dirnagl, U., Bhide, P. G., and Endres, M. (2001) Mild cerebral ischemia induces loss of cyclin-dependent kinase inhibitors and activation of cell cycle machinery before delayed neuronal cell death. J. Neurosci. 21, 5045–5053
11. Wen, Y., Yang, S., Liu, R., and Simpkins, J. W. (2005) Cell-cycle regulators are involved in transient cerebral ischemia induced neuronal apoptosis in female rats. FEBS Lett. 579, 4591–4599
12. Iaquinta, P. J., and Lees, J. A. (2007) Life and death decisions by the E2F transcription factors. Curr. Opin. Cell Biol. 19, 649–657
13. Dimova, D. K., and Dyson, N. J. (2005) The E2F transcriptional network: old acquaintances with new faces. Oncogene 24, 2810–2826
14. Dyson, N. (1998) The regulation of E2F by pRB-family proteins. Genes Dev. 12, 2245–2262
15. Frolow, M. V., and Dyson, N. J. (2004) Molecular mechanisms of E2F-dependent activation and pRB-mediated repression. J. Cell Sci. 117, 2173–2181
16. Greene, L. A., Biswas, S. C., and Liu, D. X. (2004) Cell cycle molecules and vernal neuron death: E2F at the hub. Cell Death Differ. 11, 49–60
17. Park, D. S., Morris, E. J., Brenner, R., Kerammaris, E., Padmanabhan, J., Rosenbaum, M., Shelanski, M. L., Geller, H. M., and Greene, L. A. (2000) Involvement of retinoblastoma family members and E2F/DP complexes in the death of neurons evoked by DNA damage. J. Neurosci. 20, 3104–3114
18. MacManus, J. P., Jian, M., Preston, E., Rasquinha, I., Webster, J., and Zurakowski, B. (2003) Absence of the transcription factor E2F1 attenuates brain injury and improves behavior after focal ischemia in mice. J. Cereb Blood Flow Metab. 23, 1020–1028
19. MacManus, J. P., Koch, C. J., Jian, M., Walker, T., and Zurakowski, B. (1999) Decreased brain infarct following focal ischemia in mice lacking the transcription factor E2F1. Neuroreport 10, 2711–2714
20. Greene, L. A., Liu, D. X., Troy, C. M., and Biswas, S. C. (2007) Cell cycle molecules define a pathway required for neuron death in development and disease. Biochim. Biophys. Acta 1772, 326–340
21. Liu, D. X., Nath, N., Chellappan, S. P., and Greene, L. A. (2005) Regulation of neuron survival and death by p130 and associated chromatin modifiers. Genes Dev. 19, 719–732
22. Zolotukhin, S., Potter, M., Zolotukhin, I., Sakai, Y., Loiler, S., Fraites, T. J., Jr., Choi, V. A., Phillipsberg, T., Muzychka, N., Hauswirth, W. W., Flotte, T. R., Byrne, B. J., and Snyder, R. O. (2002) Production and purification of serotype 1,2, and 5 recombinant adenov-associated viral vectors. Methods 28, 158–167
23. Liu, D. X., and Greene, L. A. (2001) Regulation of neuronal survival and death by E2F-dependent gene repression and derepression. Neuron 32, 425–438
24. O’Hare, M. J., Hou, S. T., Troy, C. M., and Greene, L. A. (2000) Induction and modulation of cerebellar granule neuron death by E2F-1. J. Biol. Chem. 275, 25358–25364
25. McClellan, K. A., Ruzhynsky, V. A., Douda, D. N., Vanderluit, J. L., Ferguson, K. L., Chen, D., Brenner, R., Park, D. S., Greene, L. A., and Slack, R. S. (2007) Unique requirement for Rb/E2F3 in neuronal migration: evidence for cell cycle-independent functions. Mol. Cell. Biol. 27, 4825–4843
26. Field, S. J., Tsai, F. Y., Kuo, F., Zubiaga, A. M., Kaelin, W. G., Jr., Livingston, D. M., Orik, S. H., and Greenberg, M. E. (1986) E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell 85, 549–561
27. Leone, G., Sears, R., Huang, E., Rempel, R., Nuckolls, F., Park, C. H., Giangranade, P., Wu, L., Saavedra, H. I., Field, S. I., Thompson, M. A., Yang, H., Fujiwara, Y., Greenberg, M. E., Orkin, S., Smith, C., and Nevins, J. R. (2001) Myc requires distinct E2F activities to induce S phase and apoptosis. Mol. Cell 8, 105–113
28. Humbert, P. O., Rogers, C., Ganiatsas, S., Landsberg, R. L., Trimarchi, J. M., Dandapani, S., Brugnara, C., Erdman, S., Schrenzel, M., Bronson, R. T., and Lees, J. A. (2000) E2F4 is essential for normal erythrocyte maturation and neonatal viability. Mol. Cell 6, 281–291
35. Liu, D. X., Biswas, S. C., and Greene, L. A. (2004) B-myb and C-myb play

36. Hansen, K., Farkas, T., Lukas, J., Holm, K., Rönnstrand, L., and Bartek, J.

34. Smith, R. A., Walker, T., Xie, X., and Hou, S. T. (2003) Involvement of the

33. Zhang, Y., Parsanejad, M., Huang, E., Qu, D., Aleyasin, H., Rousseaux, M. W., Gonzalez, Y. R., Cregan, S. P., Slack, R. S., and Park, D. S. (2008) Delayed combinatorial treatment with flavopiridol and minocycline provides longer term protection for neuronal soma but not dendrites following global ischemia. J. Neurochem. 105, 703–713

39. Moh, C., Kubiak, J. Z., Bajic, V. P., Zhu, X., Smith, M. A., and Lee, H. G. (2003) The transcription factor E2F1 modulates apoptosis of neurons. J. Neurosci. 23, 1649–1658

40. Yuan, Z., Yao, L., Li, M., Liu, S., He, W., and Lu, Y. (2011) Opposing roles for E2F1 in survival and death of cerebellar granule neurons. Neurosci. Bull. 27, 185–196

47. Kusek, J. C., Greene, R. M., and Pisano, M. M. (2001) Expression of the E2F blastoma-related p130 gene. Development 125, 4669–4679

48. Baldi, A., Esposito, V., De Luca, A., Fu, Y., Meoli, L., Giordano, G. G., Caputi, M., Baldi, F., and Giordano, A. (1997) Differential expression of Rb2/p130 and p107 in normal human tissues and in primary lung cancer. Clin. Cancer Res. 3, 1691–1697

49. LeCouter, J. E., Kablar, B., Whyte, P. F., Ying, C., and Rudnicki, M. A. (1998) Strain-dependent embryonic lethality in mice lacking the retinoblastoma-related p130 gene. Development 125, 4669–4679